Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-3 long-term inclisiran versus evolocumab extension study
2016-003815-37Phase 2Unknown
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of inclisiran in hypercholesterolemia and cardiac morbidity (2 arms), sponsored by Novartis. Primary endpoint: Primary Endpoint (Group 1; inclisiran only arm). Status: unknown.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2016-003815-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003815-37.